このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Recruitment Messages for Current Smokers Recently Diagnosed With Cancer

2022年7月20日 更新者:University of Oklahoma

A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial

The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer. To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures. We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.

調査の概要

詳細な説明

Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.

Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.

Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.

研究の種類

介入

入学 (実際)

99

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • Jordan Neil

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Speak and understand English
  • A recent cancer diagnosis (within the past 24 months)
  • 18 years or older
  • Report any cigarette use within the past 30 days

Exclusion Criteria:

  • Do not speak or understand English
  • Have not been diagnosed with cancer within the past 24 months
  • Below the age of 18
  • Does not report any cigarette use within the past 30 days

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:階乗代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
偽コンパレータ:Control
The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
Does not include any of the three message factors.
実験的:Proximal x Cost x Loss
Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
実験的:Proximal x Cost x Gain
Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
実験的:Proximal x Benefit x Gain
Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
実験的:Proximal x Benefit x Loss
Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
実験的:Distal x Cost x Gain
Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
実験的:Distal x Cost x Loss
Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
実験的:Distal x Benefit x Loss
Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
実験的:Distal x Benefit x Gain
Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Difference in intent to talk to a physician about participating in a smoking cessation study between factors.
時間枠:Within 30 minutes
The main effect within each message factor level was examined using ANOVA and compared with the control condition.
Within 30 minutes

二次結果の測定

結果測定
メジャーの説明
時間枠
Predictors of intent to talk to a physician about participating in a smoking cessation study.
時間枠:Within 30 minutes
Other message evaluation and effectiveness measures were collected and explored in a multivariable model predicting intent to talk to a physician.
Within 30 minutes

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jordan Neil, Ph.D.、TSET Health Promotion Research Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年2月11日

一次修了 (実際)

2019年4月1日

研究の完了 (実際)

2019年4月2日

試験登録日

最初に提出

2022年7月13日

QC基準を満たした最初の提出物

2022年7月20日

最初の投稿 (実際)

2022年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2022年7月22日

QC基準を満たした最後の更新が送信されました

2022年7月20日

最終確認日

2022年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する